Cargando…
The Payer License Agreement, or “Netflix model,” for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition
BACKGROUND AND AIMS: High unit prices of treatments limit access. For epidemics like that of hepatitis C virus (HCV), reduced treatment access increases prevalence and incidence, making the infectious disease increasingly difficult to manage. The objective of the current study was to construct and t...
Autores principales: | Matthews, David W., Coleman, Samantha, Razavi, Homie, Izaret, Jean‐Manuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314612/ https://www.ncbi.nlm.nih.gov/pubmed/35289467 http://dx.doi.org/10.1111/liv.15245 |
Ejemplares similares
-
Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID‐19
por: Blach, Sarah, et al.
Publicado: (2021) -
Optimization of hepatitis C virus screening strategies by birth cohort in Italy
por: Kondili, Loreta A., et al.
Publicado: (2020) -
Ecological interactions and the Netflix problem
por: Desjardins-Proulx, Philippe, et al.
Publicado: (2017) -
New forms of internationalisation? The impact of Netflix
in Australia
por: Cunningham, Stuart, et al.
Publicado: (2020) -
Breaking New Ground: Incentivizing Innovative Caregiving Programs
por: Whiting, C Grace, et al.
Publicado: (2021)